U.S. Markets closed
  • S&P 500

    4,158.24
    +100.40 (+2.47%)
     
  • Dow 30

    33,212.96
    +575.77 (+1.76%)
     
  • Nasdaq

    12,131.13
    +390.48 (+3.33%)
     
  • Russell 2000

    1,887.90
    +49.66 (+2.70%)
     
  • Crude Oil

    115.07
    +0.98 (+0.86%)
     
  • Gold

    1,857.30
    +3.40 (+0.18%)
     
  • Silver

    22.14
    +0.17 (+0.77%)
     
  • EUR/USD

    1.0739
    +0.0006 (+0.0537%)
     
  • 10-Yr Bond

    2.7430
    -0.0130 (-0.47%)
     
  • Vix

    25.72
    -1.78 (-6.47%)
     
  • GBP/USD

    1.2631
    +0.0025 (+0.2021%)
     
  • USD/JPY

    127.0850
    -0.0170 (-0.0134%)
     
  • BTC-USD

    28,798.84
    -272.75 (-0.94%)
     
  • CMC Crypto 200

    625.79
    -3.71 (-0.59%)
     
  • FTSE 100

    7,585.46
    +20.54 (+0.27%)
     
  • Nikkei 225

    26,781.68
    +176.84 (+0.66%)
     

AngioDynamics: Q2 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of AngioDynamics (NASDAQ:ANGO) were unchanged in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were down 83.33% year over year to $0.01, which beat the estimate of ($0.02).

Revenue of $72,770,000 rose by 3.95% year over year, which beat the estimate of $67,350,000.

Looking Ahead

AngioDynamics reaffirmed FY21 adjusted EPS guidance of $0.00 to $0.05 and sales forecast of $278 million to $284 million.

Conference Call Details

Date: Jan 07, 2021

View more earnings on ANGO

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/r4ork9sm

Recent Stock Performance

Company's 52-week high was at $17.24

52-week low: $7.48

Price action over last quarter: Up 34.25%

Company Description

AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.